CTLA4 and neoplasm: Rejection of the irradiated and abscopal TSA tumours in mice treated with 8GyX3+anti-CTLA4 was abrogated in Batf3−/− and interferon-α/β-receptor-1 (IFNAR1)−/− mice, demonstrating the requirement for CD8α+ TIDCs responsive to IFNβ (Supplementary Fig. 2a,b).